Trial Details

COMPLETED
Basic Information
Clinical ID c1199
Identifier NCT00295282
Trial Title A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis
Trial URL Visit Original Page
Study Information
Study Results

NO

Conditions Ulcerative Colitis
Interventions DRUG: MDX-1100 (anti-CXCL10 human monoclonal antibody)
Participant Information
Sponsor Bristol-Myers Squibb
City Los Angeles
Country/Region United States
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT, OLDER_ADULT
Study Design
Study Type INTERVENTIONAL
Phase PHASE1
Time Information
Start Date 2025-01-06
Primary Completion Date 2025-01-08
Completion Date 2025-01-08